Every S-1 that bioAffinity Technologies, Inc. (BIAF) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow BIAF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIAF filings page.
bioAffinity Technologies filed Amendment No. 1 to its Registration Statement on Form S-1. The amendment is narrowly focused and is being used to add specific deal-related documents as exhibits, rather than to change the overall terms of the planned offering.
The company is filing the form of Placement Agency Agreement with WallachBeth Capital LLC, along with the form of Pre-Funded Warrant and the form of Placement Agent Warrant, as new exhibits. The rest of the S-1 remains unchanged and is incorporated by reference. The amendment also restates standard undertakings on indemnification of directors and officers and includes updated signature pages from the company’s chief executive officer, chief financial officer, and directors.
bioAffinity Technologies, Inc. is conducting a primary offering of 2,631,579 shares of common stock, together with pre-funded and placement agent warrants and the shares issuable upon their exercise. The assumed price is $1.52 per share, implying estimated net proceeds of about $3.4 million for working capital and general corporate purposes.
The company focuses on noninvasive lung diagnostics, led by its CyPath® Lung test, which showed 92% sensitivity, 87% specificity, and 88% accuracy for small pulmonary nodules in a clinical trial. CyPath® Lung unit sales grew 146% year over year in first-quarter 2026, and a new multicenter clinical trial began enrolling in March 2026.
bioAffinity reported $1.4 million in revenue for the quarter ended March 31, 2026, and $6.2 million and $9.4 million in 2025 and 2024, respectively, but had an accumulated deficit of $72.2 million and $3.1 million in cash. Its auditor raised substantial doubt about its ability to continue as a going concern, and management indicates existing cash supports operations only through June 2026 without additional financing.
bioAffinity Technologies, Inc. has filed a resale registration for up to 497,483 shares of common stock on behalf of existing investors. The shares consist of 365,603 warrant shares and 131,880 shares issuable upon conversion of Series B preferred stock after anti-dilution adjustments. The company will not sell shares in this offering and will receive no proceeds from stockholder resales, other than any cash paid if warrants are exercised. As of December 31, 2025, 4,498,675 common shares were outstanding, rising to 4,996,155 shares if all registered warrant and conversion shares are issued. bioAffinity develops noninvasive lung cancer diagnostics, including its CyPath® Lung test, which showed 92% sensitivity and 87% specificity in a clinical trial and recently posted 146% unit sales growth year over year in the first quarter of 2026.
bioAffinity Technologies, Inc. is registering a primary offering of up to 729,927 shares of common stock, up to 729,927 pre-funded warrants, placement agent warrants for up to 21,898 shares, and up to 751,825 shares underlying these warrants. The company estimates net proceeds of about $3.4 million, assuming $4.0 million in gross sales at an assumed price of $5.48 per share. Shares outstanding would increase from 1,375,102 to 2,105,029 if all common shares (and no pre-funded warrants) are sold. The best-efforts offering has no minimum, so proceeds may be significantly lower, and there is no escrow. The company recently completed a 1-for-30 reverse stock split and is working to regain Nasdaq compliance on minimum bid price and stockholders’ equity.
bioAffinity Technologies, Inc. filed an S-1 registration disclosing an assumed public offering price of $5.48 per share and pro forma capital impacts tied to that offering. The company reported a historical net tangible book value per share of $(1.30) as of June 30, 2025. Pro forma adjustments related to the offering increase net tangible book value by $2.06 to a pro forma as adjusted net tangible book value per share of $0.76. The filing shows a reported dilution to new investors of $4.72 per share. Additional disclosed items include conversion mechanics for Series B Convertible Preferred Stock (conversion price noted as $6.90 per share) and line items for additional paid-in capital and total capitalization figures included in the filing tables.